Development of a semi-empirical physical model for transient NO emissions prediction from a high-speed diesel engine.

With emissions regulations becoming increasingly restrictive and the advent of real driving emissions limits, control of engine-out NO emissions remains an important research topic for diesel engines. Progress in experimental engine development and computational modelling has led to the generation of a large amount of high-fidelity emissions and in-cylinder data, making it attractive to use data-driven emissions prediction and control models. While pure data-driven methods have shown robustness in NO prediction during steady-state engine operation, deficiencies are found under transient operation and at engine conditions far outside the training range.

AssemblyQC: a Nextflow pipeline for reproducible reporting of assembly quality.

Summary: Genome assembly projects have grown exponentially due to breakthroughs in sequencing technologies and assembly algorithms. Evaluating the quality of genome assemblies is critical to ensure the reliability of downstream analysis and interpretation. To fulfil this task, we have developed the AssemblyQC pipeline that performs file-format validation, contaminant checking, contiguity measurement, gene- and repeat-space completeness quantification, telomere inspection, taxonomic assignment, synteny alignment, scaffold examination through Hi-C contact-map visualization, and assessments of completeness, consensus quality and phasing through k-mer analysis.

Modifying the Substrate-Dependent Pd/FeO Catalyst-Support Synergism with ZnO Atomic Layer Deposition.

Low-loading Pd supported on FeO nanoparticles was synthesized. A common nanocatalyst system with previously reported synergistic enhancement of reactivity that is attributed to the electronic interactions between Pd and the FeO support. FeO-selective precoalescence overcoating with ZnO atomic layer deposition (ALD), using Zn(CHCH) and HO as precursors, dampens competitive hydrogenation reactivity at FeO-based sites.

The Africa non-communicable diseases (NCD) Open Lab: Impact of a portfolio of clinical studies to deepen the understanding of NCDs in sub-Saharan Africa.

Background: Clinical research in sub-Saharan Africa (SSA) has often focussed on communicable diseases. However, with the increasing burden of non-communicable diseases (NCDs), there is a need for Africa-specific NCD research.

Methods: GSK established the Africa NCD Open Lab in 2014.

First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug.

Background: The clinical candidate alpibectir augments the activity of, and overcomes resistance to, the anti-TB drug ethionamide in vitro and in vivo.

Objectives: A Phase 1, double-blind, randomized, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics (PK) and food effect of alpibectir administered as single and multiple oral doses in healthy volunteers (NCT04654143).

Methods: Eighty participants were randomized.